Watch KLRS. Know when insiders buy.
One email the day a filing lands. Free.
KLRS
Kalaris Therapeutics, Inc.
3.20
+0.04 +1.27%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
84
PASS · shorts 84
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $76.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$44.3MNET CASH —52W 3.16 – 10.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$12.4M | −$11.5M | — | -0.48 | −$11M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$11.8M | −$10.9M | — | -0.46 | −$11.6M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$10.8M | −$10M | — | -0.44 | −$7.1M | $17K | −$7.1M | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | −$12.7M | −$11.9M | — | -0.64 | −$11.3M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$12.3M | −$11.3M | — | -0.61 | −$12.5M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$10.4M | −$10.2M | — | -2.52 | −$7.4M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.1M | −$22M | — | -16.33 | −$7.9M | — | — | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$37.8M | −$38.1M | — | -28.16 | −$4.3M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$4.2M | −$5.7M | — | -4.26 | −$4M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$2.6M | −$3.4M | — | -2.60 | −$4.5M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$62.4M | −$59.7M | — | -40.79 | −$30.7M | — | — | Mar 7 |
| Q3 2023 · Sep 30 | — | — | — | −$47M | −$44.3M | — | -0.39 | −$34.5M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$46.2M | −$43.4M | — | -2.85 | −$38.4M | $200K | −$38.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$51.7M | −$69.2M | — | -51.77 | −$20.7M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$199.9M | −$190.4M | — | -42.09 | −$124.5M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$171.2M | −$168.7M | — | -2.20 | −$142.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$169.8M | −$172M | — | -2.74 | −$106.3M | $26K | −$106.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$71.3M | −$69.8M | — | -2.59 | −$60.8M | $235K | −$61M | — | — |
Every number comes from Kalaris Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.